Serum Biomarkers of Myocardial Remodeling and Coronary Dysfunction in Early Stages of Hypertrophic Cardiomyopathy in the Young.

Hypertrophic cardiomyopathy: a systematic review. JAMA (2002) 9.15

Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med (2004) 7.80

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21

Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19

Design and validation of Segment--freely available software for cardiovascular image analysis. BMC Med Imaging (2010) 3.76

Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol (2006) 3.12

The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res (2005) 2.62

HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace (2011) 2.54

Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail (2010) 2.40

American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J (2003) 2.36

Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr (2009) 2.21

Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol (2000) 1.99

Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart (2000) 1.66

Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. Cardiovasc Res (2003) 1.61

Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res (2003) 1.51

Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation (2003) 1.48

Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47

T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging (2013) 1.35

Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol (2007) 1.29

Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol (2011) 1.03

Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol (2009) 1.02

Targeting adhesion molecules in cardiovascular disorders. Cardiovasc Hematol Disord Drug Targets (2008) 1.00

Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95

Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J (2009) 0.94

Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J (2004) 0.93

Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci (2007) 0.91

Quantifying coronary sinus flow and global LV perfusion at 3T. BMC Med Imaging (2009) 0.91

Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol (2006) 0.90

Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res (2001) 0.89

Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep (2008) 0.88

Serum collagen markers and heart failure. Cardiovasc Hematol Disord Drug Targets (2012) 0.85

Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs (2005) 0.85

Peripheral vascular endothelial function in patients with hypertrophic cardiomyopathy. Am J Cardiol (2010) 0.82

Genetic variations in hypoxia response genes influence hypertrophic cardiomyopathy phenotype. Pediatr Res (2012) 0.82

Young patients with hypertrophic cardiomyopathy, but not subjects at risk, show decreased myocardial perfusion reserve quantified with CMR. Eur Heart J Cardiovasc Imaging (2014) 0.80

Submaximal adenosine-induced coronary hyperaemia with 12 h caffeine abstinence: implications for clinical adenosine perfusion imaging tests. Clin Physiol Funct Imaging (2014) 0.80

Peripheral microvascular function is altered in young individuals at risk for hypertrophic cardiomyopathy and correlates with myocardial diastolic function. Am J Physiol Heart Circ Physiol (2015) 0.79

Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Hypertension (2013) 0.78

AAV-mediated administration of myostatin pro-peptide mutant in adult Ldlr null mice reduces diet-induced hepatosteatosis and arteriosclerosis. PLoS One (2013) 0.78

Elective orthopedic and cardiopulmonary bypass surgery causes a reduction in serum endostatin levels. Eur J Med Res (2014) 0.77

Regional Stress-Induced Ischemia in Non-fibrotic Hypertrophied Myocardium in Young HCM Patients. Pediatr Cardiol (2015) 0.76

Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. J Intern Med (2015) 0.79

The association between endostatin and kidney disease and mortality in patients with type 2 diabetes. Diabetes Metab (2016) 0.75